Earnings History Data for VistaGen Therapeutics, Inc. (VTGN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
23-06-2022	AH	4:20 PM ET (Jun 23)	VTGN	VistaGen Therapeutics, Inc.	218.92	-0.08	-0.06	-0.20	VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M [6/23/2022 4:22 PM]	0.9679	-0.07 (-6.93%)	1.02	-0.02 (-1.92%)	0.87 - 3.55	2,080,145	1,180,000	5,615
VistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21M [6/23/2022 4:22 PM] VistaGen stock down 7% on disappointing FY result [6/24/2022 1:55 PM] VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder [Jun-22-22 08:30AM] VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update [Jun-23-22 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates [Jun-23-22 05:35PM]
10-02-2022	AH	4:20 PM ET (Feb 10)	VTGN	VistaGen Therapeutics, Inc.	311.54	-0.05	-0.08	-0.07	VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M [2/10/2022 4:32 PM]	1.51	-0.03 (-1.95%)	1.64	0.10 (6.49%)	1.40 - 3.55	1,437,833	1,350,000	4,617
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M [2/10/2022 4:32 PM] VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update [Feb-10-22 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates [Feb-10-22 05:55PM]
10-11-2021	AH	4:25 PM ET (Nov 10)	VTGN	VistaGen Therapeutics, Inc.	476.47	-0.07	-0.05	-0.05	VistaGen Therapeutics EPS misses by $0.01, beats on revenue [11/10/2021 4:28 PM]	2.35	0.10 (4.44%)	2.27	0.02 (0.89%)	0.65 - 3.55	3,053,487	1,170,000	421
VistaGen Therapeutics EPS misses by $0.01, beats on revenue [11/10/2021 4:28 PM] VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update [Nov-10-21 04:20PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates [Nov-10-21 07:05PM] VISTAGEN THERAPEUTIC (VSTA) Q2 2022 Earnings Call Transcript [Nov-11-21 04:31AM]
12-08-2021	AH	4:15 PM ET (Aug 12)	VTGN	VistaGen Therapeutics, Inc.	530.19	-0.04	-0.05	-0.07	VistaGen Therapeutics EPS beats by $0.01, misses on revenue [8/12/2021 4:36 PM]	2.78	0.03 (1.09%)	2.75	0.0 (0.00%)	0.56 - 3.55	918,048	830,000	690
VistaGen Therapeutics EPS beats by $0.01, misses on revenue [8/12/2021 4:36 PM] VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update [Aug-12-21 04:25PM] VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates [Aug-12-21 08:05PM] VISTAGEN THERAPEUTIC (VSTA) Q1 2022 Earnings Call Transcript [Aug-13-21 06:31AM]
29-06-2021	AH		VTGN	Vistagen Therapeutics, Inc.	377.00	-0.20	-0.05	0.00	VistaGen Therapeutics EPS misses by $0.27, beats on revenue [6/29/2021 4:17 PM]	3.17	0.49 (18.28%)	2.69	0.01 (0.37%)	0.46 - 3.18	6,844,214	4,650,000	20,686
VistaGen Therapeutics EPS misses by $0.27, beats on revenue [6/29/2021 4:17 PM] VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update [Jun-29-21 04:15PM] Why VistaGen Therapeutics Stock Jumped Today [Jun-30-21 04:14PM]
11-02-2021	AH		VTGN	VistaGen Therapeutics, Inc.	261.85	-0.07	-0.05	-0.15	VistaGen Therapeutics EPS misses by $0.02, beats on revenue [2/11/2021 4:54 PM]	1.90	-0.08 (-4.04%)	1.98	0.0 (0.00%)	0.30 - 2.94	2,448,488	2,554,831	42,576
VistaGen Therapeutics EPS misses by $0.02, beats on revenue [2/11/2021 4:54 PM]
12-11-2020	AH		VTGN	VistaGen Therapeutics, Inc.	48.17	-0.05	0.02	-0.13	VistaGen Therapeutics EPS of -$0.05 [11/12/2020 5:41 PM]	0.70	0.0 (-0.37%)	0.70	0.0 (-0.37%)	0.29 - 1.15	217,681	507,776	13,115